Evidence map›Paper›PMID 34393626›Full record

ReviewActa medica Lituanic2021

Review of New Clinical Aspects of Cardiac Pathology in Patients with COVID-19 Infection.

Audrė Alonderytė, Giedrius Navickas, Robertas Stasys Samalavičius, Pranas Šerpytis

Open access · diamondAbstract readReview
In one paragraph

Review in Acta medica Lituanic, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Audrė AlonderytėFaculty of Medicine, Vilnius University, Vilnius, Lithuania.
Giedrius NavickasCentre of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Robertas Stasys SamalavičiusInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, LithuaniaEmergency Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Pranas ŠerpytisCentre of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, Vilnius, LithuaniaInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, LithuaniaEmergency Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Vilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SUMMARY

backgroundCOVID-19 disease is a huge burden for society and healthcare specialists. As more information is gathered about this new disease, it becomes clear that it affects not only respiratory, but also cardiovascular system. MATERIALS AND

methodsThe aim of this review is to analyse the information about myocardial injury caused by COVID-19 and overview treatment options for these patients in publications which were published in the last 5 years. The data for this overview were collected in the PubMed database. Full-text articles were used for analysis when their title, summary, or keywords matched the purpose of the review. Only publications published in English that appeared in the last 5 years were analysed. For the analysis 14 publications were selected and analysed.

conclusionCOVID-19 infection could mimic ST-elevation myocardial infarction and it is crucial to differentiate the main cause and choose the appropriate treatment. Cardiovascular complications are related with poorer prognosis and higher mortality. This should be thoroughly considered by the healthcare specialists in order to choose appropriate treatment strategy. Patients with acute coronary syndrome (ACS) due to plaque rupture should receive dual antiplatelet therapy and full-dose anticoagulation if it is not contraindicated. Therefore, priority should be given to the acute coronary syndrome given the low evidence of new antiviral treatment effectiveness. Number of agents which are under investigation for COVID-19 may have interactions with oral antiplatelet drugs. Selected patients could receive immunosuppressive treatment as well as extracorporeal membrane oxygenation as a bridge to recovery.

Indexed as

acute coronary syndromecoronavirusmyocardial infarctiontreatment

Identifiers

PMID34393626
PMCPMC8311833
OpenAlexW3134080928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.